Aeterna Zentaris Inc.-Product Pipeline Review-2015

Aeterna Zentaris Inc.-Product Pipeline Review-2015


  • Products Id :- GMDHC07191CDB
  • |
  • Pages: 66
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Aeterna Zentaris Inc.-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Aeterna Zentaris Inc.-Product Pipeline Review-2015', provides an overview of the Aeterna Zentaris Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Aeterna Zentaris Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Aeterna Zentaris Inc. including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Aeterna Zentaris Inc.'s human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Aeterna Zentaris Inc.'s pipeline products

Reasons To Buy

Evaluate Aeterna Zentaris Inc.'s strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Aeterna Zentaris Inc. in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Aeterna Zentaris Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Aeterna Zentaris Inc. and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Aeterna Zentaris Inc.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Aeterna Zentaris Inc. and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Aeterna Zentaris Inc. Snapshot 6

Aeterna Zentaris Inc. Overview 6

Key Information 6

Key Facts 6

Aeterna Zentaris Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

Aeterna Zentaris Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Aeterna Zentaris Inc.-Pipeline Products Glance 12

Aeterna Zentaris Inc.-Late Stage Pipeline Products 12

Filing rejected/Withdrawn Products/Combination Treatment Modalities 12

Phase III Products/Combination Treatment Modalities 13

Aeterna Zentaris Inc.-Clinical Stage Pipeline Products 14

Phase II Products/Combination Treatment Modalities 14

Phase I Products/Combination Treatment Modalities 15

Aeterna Zentaris Inc.-Early Stage Pipeline Products 16

IND/CTA Filed Products/Combination Treatment Modalities 16

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Aeterna Zentaris Inc.-Drug Profiles 19

macimorelin acetate 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

zoptarelin doxorubicin 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

ozarelix 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

perifosine 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

AEZS-120 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AEZS-124 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

AEZS-125 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

AEZS-126 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

AEZS-127 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

AEZS-129 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

AEZS-134 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

AEZS-136 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

AEZS-137 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AEZS-138 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

AN-207 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecules for Undisclosed Indication 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Small Molecules to Inhibit ERK2 and Aurora B Kinase for Cancer 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Aeterna Zentaris Inc.-Pipeline Analysis 41

Aeterna Zentaris Inc.-Pipeline Products by Target 41

Aeterna Zentaris Inc.-Pipeline Products by Route of Administration 43

Aeterna Zentaris Inc.-Pipeline Products by Molecule Type 44

Aeterna Zentaris Inc.-Pipeline Products by Mechanism of Action 45

Aeterna Zentaris Inc.-Recent Pipeline Updates 47

Aeterna Zentaris Inc.-Dormant Projects 58

Aeterna Zentaris Inc.-Discontinued Pipeline Products 59

Discontinued Pipeline Product Profiles 59

AEZS-115 59

AEZS-123 59

AEZS-131 59

AEZS-132 60

AN-215 60

AN-238 60

perifosine 60

teverelix 61

Aeterna Zentaris Inc.-Company Statement 62

Aeterna Zentaris Inc.-Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

Aeterna Zentaris Inc., Key Information 6

Aeterna Zentaris Inc., Key Facts 6

Aeterna Zentaris Inc.-Pipeline by Indication, 2015 8

Aeterna Zentaris Inc.-Pipeline by Stage of Development, 2015 10

Aeterna Zentaris Inc.-Monotherapy Products in Pipeline, 2015 11

Aeterna Zentaris Inc.-Filing rejected/Withdrawn, 2015 12

Aeterna Zentaris Inc.-Phase III, 2015 13

Aeterna Zentaris Inc.-Phase II, 2015 14

Aeterna Zentaris Inc.-Phase I, 2015 15

Aeterna Zentaris Inc.-IND/CTA Filed, 2015 16

Aeterna Zentaris Inc.-Preclinical, 2015 17

Aeterna Zentaris Inc.-Discovery, 2015 18

Aeterna Zentaris Inc.-Pipeline by Target, 2015 41

Aeterna Zentaris Inc.-Pipeline by Route of Administration, 2015 43

Aeterna Zentaris Inc.-Pipeline by Molecule Type, 2015 44

Aeterna Zentaris Inc.-Pipeline Products by Mechanism of Action, 2015 46

Aeterna Zentaris Inc.-Recent Pipeline Updates, 2015 47

Aeterna Zentaris Inc.-Dormant Developmental Projects,2015 58

Aeterna Zentaris Inc.-Discontinued Pipeline Products, 2015 59

Aeterna Zentaris Inc., Subsidiaries 64

List of Figures

Aeterna Zentaris Inc.-Pipeline by Top 10 Indication, 2015 8

Aeterna Zentaris Inc.-Pipeline by Stage of Development, 2015 10

Aeterna Zentaris Inc.-Monotherapy Products in Pipeline, 2015 11

Aeterna Zentaris Inc.-Pipeline by Top 10 Target, 2015 41

Aeterna Zentaris Inc.-Pipeline by Top 10 Route of Administration, 2015 43

Aeterna Zentaris Inc.-Pipeline by Top 10 Molecule Type, 2015 44

Aeterna Zentaris Inc.-Pipeline Products by Top 10 Mechanism of Action, 2015 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Aeterna Zentaris Inc.; Aeterna Zentaris Inc. - Key Therapeutics; Aeterna Zentaris Inc. - Pipeline Overview and Promising Molecules; Aeterna Zentaris Inc. - News; Aeterna Zentaris Inc. - Latest Updates; Aeterna Zentaris Inc. - Pipeline; Aeterna Zentaris Inc. - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97575
Site License
USD 3000 INR 195150
Corporate User License
USD 4500 INR 292725

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com